Class-specific relative genetic contribution for key antiretroviral drugs | Zendy

Marco Siccardi | Zendy; Adeniyi Olagunju | Zendy; Marco Simiele | Zendy; Antonio D’Avolio | Zendy; Andrea Calcagno | Zendy; Giovanni Di Perri | Zendy; Stefano Bonora | Zendy; Andrew Owen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Class-specific relative genetic contribution for key antiretroviral drugs

Author(s) -

Marco Siccardi,

Adeniyi Olagunju,

Marco Simiele,

Antonio D’Avolio,

Andrea Calcagno,

Giovanni Di Perri,

Stefano Bonora,

Andrew Owen

Publication year - 2015

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkv207

Subject(s) - atazanavir , efavirenz , raltegravir , ritonavir , nevirapine , etravirine , lopinavir , pharmacology , darunavir , pharmacokinetics , pharmacogenetics , maraviroc , medicine , chemistry , virology , viral load , genotype , human immunodeficiency virus (hiv) , antiretroviral therapy , biochemistry , gene

Antiretroviral pharmacokinetics is defined by numerous factors affecting absorption, distribution, metabolism and elimination. Biological processes underpinning drug distribution are only partially characterized and multiple genetic factors generate cumulative or antagonistic interactions, which complicates the implementation of pharmacogenetic markers. The aim of this study was to assess the degree to which heredity influences pharmacokinetics through the quantification of the relative genetic contribution (rGC) for key antiretrovirals.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research